Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier-Reference-Cited by-同舟云学术

Central Effects of Beta-Blockers May Be Due to Nitric Oxide and Hydrogen Peroxide Release Independently of Their Ability to Cross the Blood-Brain Barrier

Published:2019-01-31 Issue: Volume:13 Page:
ISSN:1662-453X
Container-title:Frontiers in Neuroscience
language:
Short-container-title:Front. Neurosci.

Author:

Laurens Claire,Abot Anne,Delarue Alain,Knauf Claude

Publisher

Frontiers Media SA

Subject

General Neuroscience

Reference33 articles.

1. Galanin enhances systemic glucose metabolism through enteric nitric oxide synthase-expressed neurons.;Abot;Mol. Metab.,2018

2. Atenolol treatment for severe infantile hemangiomas: a single-centre prospective study.;Alexopoulos;J. Eur. Acad. Dermatol. Venereol.,2018

3. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration.;Angelova;FEBS Lett.,2018

4. Endogenous nitric oxide synthesis: biological functions and pathophysiology.;Bredt;Free Radic Res.,1999

5. Side effects of beta-blocker treatments as related to the central nervous system.;Dahlof;Am. J. Med. Sci.,1990

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating experimental vs. Predicted pKa values for PET radiotracer;European Journal of Pharmaceutics and Biopharmaceutics;2024-10

2. Peripheral to brain and hippocampus crosstalk induced by exercise mediates cognitive and structural hippocampal adaptations;Life Sciences;2024-09

3. A Combined Computational and Experimental Approach to Studying Tropomyosin Kinase Receptor B Binders for Potential Treatment of Neurodegenerative Diseases;Molecules;2024-08-23

4. European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4: propranolol;The Journal of Headache and Pain;2024-07-24

5. Effects on cerebral blood flow after single doses of the β₂ agonist, clenbuterol, in healthy volunteers and patients with mild cognitive impairment or Parkinson's disease;British Journal of Clinical Pharmacology;2024-07-02